Quest Partners LLC Reduces Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Quest Partners LLC reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 51.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,677 shares of the company’s stock after selling 3,901 shares during the quarter. Quest Partners LLC’s holdings in Twist Bioscience were worth $181,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. American International Group Inc. increased its position in shares of Twist Bioscience by 0.8% during the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock worth $978,000 after purchasing an additional 213 shares in the last quarter. Caprock Group LLC grew its stake in Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after buying an additional 220 shares during the last quarter. Arizona State Retirement System increased its position in Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock worth $798,000 after buying an additional 308 shares during the period. CWM LLC lifted its stake in Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Twist Bioscience by 31.3% during the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after acquiring an additional 546 shares during the last quarter.

Twist Bioscience Price Performance

Shares of TWST stock opened at $46.95 on Monday. The business’s fifty day moving average price is $47.68 and its 200 day moving average price is $42.77. The firm has a market capitalization of $2.75 billion, a PE ratio of -13.97 and a beta of 1.76. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.01) EPS. Equities research analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, CFO Adam Laponis sold 842 shares of Twist Bioscience stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares of the company’s stock, valued at $3,599,873.82. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Twist Bioscience news, CFO Adam Laponis sold 842 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares in the company, valued at approximately $3,599,873.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 1,732 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $49.41, for a total transaction of $85,578.12. Following the completion of the sale, the chief executive officer now directly owns 505,846 shares in the company, valued at approximately $24,993,850.86. The disclosure for this sale can be found here. Insiders have sold 17,388 shares of company stock valued at $776,599 in the last quarter. 3.92% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TWST. Guggenheim initiated coverage on shares of Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. JPMorgan Chase & Co. raised their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Robert W. Baird increased their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Finally, TD Cowen boosted their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.